I-Mab
NASDAQ:IMAB

Watchlist Manager
I-Mab Logo
I-Mab
NASDAQ:IMAB
Watchlist
Price: 4.18 USD 4.76% Market Closed
Market Cap: 341.3m USD

Relative Value

There is not enough data to reliably calculate the relative value of IMAB.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

IMAB Relative Value
Base Case
Not Available
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
vs Industry
32
Median 3Y
-7
Median 5Y
19.1
Industry
7.9
vs History
vs Industry
11
Median 3Y
-5.2
Median 5Y
-5.1
Industry
24
Forward
-205.3
vs History
39
vs Industry
Median 3Y
2.5
Median 5Y
4.9
Industry
21.6
vs History
39
vs Industry
Median 3Y
2.9
Median 5Y
5.7
Industry
23.7
vs History
3
vs Industry
75
Median 3Y
3.2
Median 5Y
3.9
Industry
3.4
vs History
vs Industry
47
Median 3Y
-14.7
Median 5Y
6.5
Industry
8.3
vs History
vs Industry
50
Median 3Y
0
Median 5Y
0
Industry
10.3
vs History
vs Industry
17
Median 3Y
-0
Median 5Y
-1.3
Industry
6.7
Forward
-15
vs History
vs Industry
15
Median 3Y
-0
Median 5Y
-1.3
Industry
7.2
Forward
-62.3
vs History
30
vs Industry
17
Median 3Y
0.1
Median 5Y
1.4
Industry
8.2
vs History
30
vs Industry
13
Median 3Y
0.1
Median 5Y
1.5
Industry
6.7
vs History
38
vs Industry
4
Median 3Y
2.6
Median 5Y
3.8
Industry
5.7

Multiples Across Competitors

IMAB Competitors Multiples
I-Mab Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
CN
I-Mab
NASDAQ:IMAB
341.3m USD 0 -64 -104.6 -64.6
FR
Pharnext SCA
OTC:PNEXF
6T USD 34 067 817 -161 919.3 -196 621.7 -194 378
US
Abbvie Inc
NYSE:ABBV
394.3B USD 6.6 167.9 16.3 23.1
US
Amgen Inc
NASDAQ:AMGN
172.8B USD 4.8 24.7 17.9 17.9
US
Gilead Sciences Inc
NASDAQ:GILD
150.5B USD 5.2 18.6 12.5 12.5
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
112.3B USD 9.6 30.6 22.4 23.4
US
Epizyme Inc
F:EPE
94.1B EUR 2 067.9 -527.7 -574.6 -559.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
74.1B USD 5.2 16.2 15.3 17.4
AU
CSL Ltd
ASX:CSL
88.6B AUD 3.8 19.6 13.2 16.4
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
56.7B USD 17.7 1 300.9 171.3 207.7
NL
argenx SE
XBRU:ARGX
47.9B EUR 15.5 36.4 63.1 64.9
P/S Multiple
Revenue Growth P/S to Growth
CN
I-Mab
NASDAQ:IMAB
Average P/S: 3 406 995.3
Not Available
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
34 067 817
N/A N/A
US
Abbvie Inc
NYSE:ABBV
6.6
9%
0.7
US
Amgen Inc
NASDAQ:AMGN
4.8
5%
1
US
Gilead Sciences Inc
NASDAQ:GILD
5.2
4%
1.3
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
9.6
10%
1
US
E
Epizyme Inc
F:EPE
2 067.9
N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
5.2
6%
0.9
AU
CSL Ltd
ASX:CSL
3.8
5%
0.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
17.7
46%
0.4
NL
argenx SE
XBRU:ARGX
15.5
49%
0.3
P/E Multiple
Earnings Growth PEG
CN
I-Mab
NASDAQ:IMAB
Average P/E: 201.9
Negative Multiple: -64
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -161 919.3 N/A N/A
US
Abbvie Inc
NYSE:ABBV
167.9
89%
1.9
US
Amgen Inc
NASDAQ:AMGN
24.7
45%
0.5
US
Gilead Sciences Inc
NASDAQ:GILD
18.6
190%
0.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
30.6
N/A N/A
US
E
Epizyme Inc
F:EPE
Negative Multiple: -527.7 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.2
9%
1.8
AU
CSL Ltd
ASX:CSL
19.6
11%
1.8
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
1 300.9
N/A N/A
NL
argenx SE
XBRU:ARGX
36.4
40%
0.9
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
CN
I-Mab
NASDAQ:IMAB
Average EV/EBITDA: 41.5
Negative Multiple: -104.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -196 621.7 N/A N/A
US
Abbvie Inc
NYSE:ABBV
16.3
14%
1.2
US
Amgen Inc
NASDAQ:AMGN
17.9
11%
1.6
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
7%
1.8
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
22.4
16%
1.4
US
E
Epizyme Inc
F:EPE
Negative Multiple: -574.6 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
15.3
11%
1.4
AU
CSL Ltd
ASX:CSL
13.2
8%
1.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
171.3
N/A N/A
NL
argenx SE
XBRU:ARGX
63.1
807%
0.1
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
CN
I-Mab
NASDAQ:IMAB
Average EV/EBIT: 47.9
Negative Multiple: -64.6
N/A N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -194 378 N/A N/A
US
Abbvie Inc
NYSE:ABBV
23.1
30%
0.8
US
Amgen Inc
NASDAQ:AMGN
17.9
20%
0.9
US
Gilead Sciences Inc
NASDAQ:GILD
12.5
12%
1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
23.4
16%
1.5
US
E
Epizyme Inc
F:EPE
Negative Multiple: -559.3 N/A N/A
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.4
13%
1.3
AU
CSL Ltd
ASX:CSL
16.4
11%
1.5
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
207.7
N/A N/A
NL
argenx SE
XBRU:ARGX
64.9
N/A N/A